ID   DND-41
AC   CVCL_2022
SY   DND 41; DND41; Dnd41
DR   EFO; EFO_0007074
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473521
DR   BioSample; SAMN10988451
DR   CCLE; DND41_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   Cell_Model_Passport; SIDM00946
DR   Cosmic; 721705
DR   Cosmic; 801725
DR   Cosmic; 913405
DR   Cosmic; 933551
DR   Cosmic; 944546
DR   Cosmic; 998728
DR   Cosmic; 1037686
DR   Cosmic; 1115582
DR   Cosmic; 1118466
DR   Cosmic; 1151777
DR   Cosmic; 1175127
DR   Cosmic; 1224375
DR   Cosmic; 1281366
DR   Cosmic; 1330488
DR   Cosmic; 1375579
DR   Cosmic; 1524795
DR   Cosmic; 1664514
DR   Cosmic; 1641377
DR   Cosmic; 1760521
DR   Cosmic; 2165710
DR   Cosmic; 2602912
DR   Cosmic-CLP; 1297446
DR   DepMap; ACH-000981
DR   DSMZ; ACC-525
DR   ENCODE; ENCBS282AAA
DR   ENCODE; ENCBS439IWV
DR   ENCODE; ENCBS688JZQ
DR   GDSC; 1297446
DR   GEO; GSM886986
DR   GEO; GSM888055
DR   GEO; GSM1669739
DR   IARC_TP53; 10567
DR   LiGeA; CCLE_079
DR   LINCS_LDP; LCL-1036
DR   Lonza; 1410
DR   NCBI_Iran; C183
DR   PharmacoDB; DND41_302_2019
DR   Progenetix; CVCL_2022
DR   Wikidata; Q54831320
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8127147;
RX   PubMed=8641406;
RX   PubMed=9933131;
RX   PubMed=10071127;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=15472075;
RX   PubMed=17170727;
RX   PubMed=17308084;
RX   PubMed=22460905;
RX   PubMed=22675565;
RX   PubMed=27397505;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
WW   https://humantallcelllines.wordpress.com/comprehensivetable/dnd-41/
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/Dnd41_Bernstein_protocol.pdf
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: ENCODE project common cell types; tier 3.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Doubling time: ~35 hours (DSMZ).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger); Stable (MSS) (PubMed=10739008; PubMed=11226526).
CC   Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 13532; TLX3; Name(s)=TLX3-BCL11B, HOX11L2-BCL11B (PubMed=17308084; PubMed=31160637).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Gln71Ter (c.211C>T); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; p.Ala279Thr (c.835G>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593Pro (c.4778T>C); Zygosity=Heterozygous (PubMed=15472075; PubMed=22675565).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Asp1609Val (c.4826A>T); Zygosity=Heterozygous (PubMed=15472075; PubMed=22675565).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Val2443fs*35 (c.7327_7327G>TGT); Zygosity=Heterozygous (PubMed=15472075; PubMed=22675565).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (PubMed=22675565; CCLE; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 8986; PIM1; Simple; p.Gln127Ter (c.379C>T); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Asp421Asn (c.1261G>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Ser1002Asn (c.3005G>A); ClinVar=VCV000241355; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Arg373Gly (c.1117A>G); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (PubMed=10071127; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: H3K79me2 ChIP-seq epigenome analysis.
CC   Omics: H3K9ac ChIP-seq epigenome analysis.
CC   Omics: H4K20me1 ChIP-seq epigenome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.28%; Native American=0%; East Asian, North=1%; East Asian, South=0%; South Asian=4.99%; European, North=46.97%; European, South=45.76% (PubMed=30894373).
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 10,11
ST   D16S539: 10,14
ST   D5S818: 12,13
ST   D7S820: 8,12
ST   TH01: 8,10
ST   TPOX: 8,11
ST   vWA: 15,16
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   13Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 32
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=8127147;
RA   Heyman M., Grander D., Brondum-Nielsen K., Cederblad B., Liu Y.,
RA   Xu B., Einhorn S.;
RT   "Interferon system defects in malignant T-cells.";
RL   Leukemia 8:425-434(1994).
//
RX   PubMed=8641406; DOI=10.1111/j.1600-0609.1996.tb00721.x;
RA   Borgonovo Brandter L., Heyman M., Rasool O., Liu Y., Grander D.,
RA   Einhorn S.;
RT   "p16INK4/p15INK4B gene inactivation is a frequent event in malignant
RT   T-cell lines.";
RL   Eur. J. Haematol. 56:313-318(1996).
//
RX   PubMed=9933131; DOI=10.1016/S0145-2126(98)00133-7;
RA   Burger R., Hansen-Hagge T.E., Drexler H.G., Gramatzki M.;
RT   "Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines:
RT   suggestion for classification by immunophenotype and T-cell receptor
RT   studies.";
RL   Leuk. Res. 23:19-27(1999).
//
RX   PubMed=10071127; DOI=10.1016/S0145-2126(98)00146-5;
RA   Kawamura M., Ohnishi H., Guo S.X., Sheng X.-M., Minegishi M.,
RA   Hanada R., Horibe K., Hongo T., Kaneko Y., Bessho F., Yanagisawa M.,
RA   Sekiya T., Hayashi Y.;
RT   "Alterations of the p53, p21, p16, p15 and RAS genes in childhood
RT   T-cell acute lymphoblastic leukemia.";
RL   Leuk. Res. 23:115-126(1999).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=15472075; DOI=10.1126/science.1102160;
RA   Weng A.P., Ferrando A.A., Lee W., Morris J.P. IV, Silverman L.B.,
RA   Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.;
RT   "Activating mutations of NOTCH1 in human T cell acute lymphoblastic
RT   leukemia.";
RL   Science 306:269-271(2004).
//
RX   PubMed=17170727; DOI=10.1038/sj.leu.2404486;
RA   Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M.,
RA   de Vos J., MacLeod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M.,
RA   Langerak A.W.;
RT   "Human T-cell lines with well-defined T-cell receptor gene
RT   rearrangements as controls for the BIOMED-2 multiplex polymerase chain
RT   reaction tubes.";
RL   Leukemia 21:230-237(2007).
//
RX   PubMed=17308084; DOI=10.1158/0008-5472.CAN-06-2615;
RA   Nagel S., Scherr M., Kel A., Hornischer K., Crawford G.E.,
RA   Kaufmann M., Meyer C., Drexler H.G., MacLeod R.A.F.;
RT   "Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute
RT   lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation
RT   by PU.1 and HMGA1.";
RL   Cancer Res. 67:1461-1471(2007).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22675565; DOI=10.1371/journal.pone.0038463;
RA   Kalender Atak Z., De Keersmaecker K., Gianfelici V., Geerdens E.,
RA   Vandepoel R., Pauwels D., Porcu M., Lahortiga I., Brys V., Dirks W.G.,
RA   Quentmeier H., Cloos J., Cuppens H., Uyttebroeck A., Vandenberghe P.,
RA   Cools J., Aerts S.;
RT   "High accuracy mutation detection in leukemia on a selected panel of
RT   cancer genes.";
RL   PLoS ONE 7:E38463-E38463(2012).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//